Silent growth hormone secreting pituitary adenomas: IGF-1 is not sufficient to exclude growth hormone excess

Annals of Clinical Biochemistry

Volumn 44, Issue 1, 2007, Pages 89-93

  Kalavalapalli, S ^a   Reid, H ^a   Kane, J ^a   Buckler, H ^a   Trainer, P ^a   Heald, A H ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b BISHOP AUCKLAND GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; GROWTH HORMONE; OCTREOTIDE; ORAL CONTRACEPTIVE AGENT; SOMATOMEDIN C; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; THYROXINE;

ACROMEGALY; ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; CASE REPORT; CLINICAL FEATURE; FEMALE; GROWTH HORMONE SECRETING ADENOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; IMMUNOCHEMISTRY; LABORATORY TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL GLUCOSE TOLERANCE TEST; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCREENING TEST;

ACROMEGALY; ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; GROWTH HORMONE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR I;

EID: 33846494855     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/000456307779596075     Document Type: Article

References (32)

1. Giustina A, Barkan A, Casanueva F, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000; 85: 526-9
2. Sakharova AA, Dimaraki EV, Chandler WF, Barkan AL. Clinically silent somatotropinomas may be biochemically active. J Clin Endocrinol Metab 2005; 90: 2117-21
3. Yamada S, Sano T, Stefaneanu L, et al. Endocrine and morphological study of a clinically silent somatotroph adenoma of the human pituitary. J Clin Endocrinol Metab 1993; 76: 352-6
4. Horvath E, Kovacs K, Killinger DW. Silent corticotropic adenomas of the pituitary gland: a histologic, immunocytologic and ultrastructural study. Am J Pathol 1980; 98: 617-38
5. Kovacs K, Lloyd R, Horvath E, et al. Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization. Am J Pathol 1989; 134: 345-53
6. Klibanski A, Zervas NT, Kovacs K, Ridgway EC. Clinically silent hypersecretion of growth hormone in patients with pituitary tumors. J Neurosurg 1987; 66: 806-11
7. Stoffel-Wagner B, Springer W, Bidlingmaier F, Klingmuller D. A comparison of different methods for diagnosing acromegaly. Clin Endocrinol (Oxf) 1997; 46: 531-7
8. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 2002; 87: 3537-42
9. Jaffe CA, Barkan AL. Acromegaly. Recognition and treatment. Drugs 1994; 47: 425-45
10. Robert F. Electron microscopy of human pituitary tumors. In: Tindall GT, Collins WF, eds. Clinical Management of Pituitary Disorders. New York: Raven, 1979; 113-31
11. Helle SI, Omsjo IH, Cwyfan-Hughes SC, et al. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clin Endocrinol 1996; 45: 727-32
12. Stoffel-Wagner B, Springer W, Bidlingmaier F, Klingmuller D. A comparison of different methods for diagnosing acromegaly. Clin Endocrinol (Oxf) 1997; 46: 531-7
13. Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of The Growth Hormone Research Society and The Pituitary Society. J Clin Endocrinol Metab 2004; 89: 3099-102
14. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 2002; 87: 3537-42
15. Yamada S, Sano T, Stefaneanu L, et al. Endocrine and morphological study of a clinically silent somatotroph adenoma of the human pituitary. J Clin Endocrinol Metab 1993; 76: 352-6
16. Klibanski A, Zervas NT, Kovacs K, Ridgway EC. Clinically silent hypersecretion of growth hormone in patients with pituitary tumors. J Neurosurg 1987; 66: 806-11
17. Sakharova AA, Dimaraki EV, Chandler WF, Barkan AL. Clinically silent somatotropinomas may be biochemically active. J Clin Endocrinol Metab 2005; 90: 2117-21
18. Rosenfield RL, Devine N, Hunold JJ, Mauras N, Moshang Jr T, Root AW. Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. J Clin Endocrinol Metab 2005; 90: 6424-30
19. Heald A, Selby PL, White A, Gibson JM. Progestins abrogate estrogen-induced changes in the insulin-growth factor axis. Am J Obstet Gynecol 2000; 183: 593-600
20. Pokrajac-Simeunovic A, Wark G, Wieringa GE, Trainer PJ. Variability in IGF-1 assay performance undermines its contribution to the management of GH disorders. British Endocrine Society Meeting, November 2004, Endocrine Abstracts 8; p 23
21. Brabant G, von zur Muhlen A, Wuster C, et al. German KIMS Board. Serum insulin-like growth factor 1 reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 2003; 60: 53-60
22. Marzullo P, Di Somma C, Pratt KL, et al. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. J Clin Endocrinol Metab 2001; 86: 3001-8
23. Rieu M, Girard F, Bricaire H, Binoux M. The importance of insulin-like growth factor (somatomedin) measurements in the diagnosis and surveillance of acromegaly. J Clin Endocrinol Metab 1982; 55: 147-53
24. Arosio M, Garrone S, Bruzzi P, Faglia G, Minuto F, Barreca A. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) 1, and IGF-binding protein-1, -2, and -3 J. Clin Endocrinol Metab 2001; 86: 1091-8
25. Costa AC, Rossi A, Martinelli Jr CE, Machado HR, Moreira AC. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab 2002; 87: 3142-7
26. Clemmons DR, VanWyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE. Evalation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 1979; 301: 1138-42
27. Barreca A, Ciccarelli E, Minuto F, Bruzzi P, Giordano G, Camanni F. Insulin-like growth factor 1 and daily growth hormone profile in the assessment of active acromegaly. Acta Endocrinol (Copenh) 1989; 120: 629-35
28. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000; 85: 526-9
29. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993; 86: 293-9
30. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994; 41: 95-102
31. Orme SM, McNally RJQ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 1998; 83: 2730-4
32. Stoffel-Wagner B, Springer W, Bidlingmaier F, Klingmüller D. A comparison of different methods for diagnosing acromegaly. Clin Endocrinol (Oxf) 1997; 46: 531-7